(LFST) Lifestance Health - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US53228F1012

Stock: Outpatient Mental Health Services, Psychiatric Evaluations, Therapy, Telehealth

Total Rating 33

Risk 40

Buy Signal 0.16

Medical Care Facilities » Health Care Equipment
Age: 4.7y

Market Cap: 2,750m
Avg Trading Vol: 11.1M USD

ATR: 3.73%
Peers RS (IBD): 70.54

EPS (Earnings per Share)

EPS CAGR: 90.84%
EPS Trend: 89.6%

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: 18.91%
Rev. Trend: 99.1%

Last SUE: 1.36
Qual. Beats: 1

Risk 5d forecast
Volatility	59.0%
Relative Tail Risk	-16.2%

Reward TTM
Sharpe Ratio	-0.12
Alpha	-28.32

Character TTM
Beta	0.695
Beta Downside	0.314

Drawdowns 3y
Max DD	59.68%
CAGR/Max DD	0.19

Description: LFST Lifestance Health January 16, 2026

LifeStance Health Group, Inc. (NASDAQ: LFST) operates a nationwide network of outpatient mental-health clinics that serve children, adolescents, adults, and seniors. Its clinical portfolio includes psychiatric evaluations, medication management, psychological and neuropsychological testing, and individual, family, and group therapy for conditions such as anxiety, depression, bipolar disorder, eating disorders, psychosis, and PTSD. Patients can receive care either in-person at its centers or remotely via a proprietary tele-health platform.

Key operational metrics from the most recent filing show FY 2023 revenue of roughly $1.0 billion, up about 15 % year-over-year, driven by a 12 % increase in clinic count (now > 300 locations) and a 30 % share of visits delivered virtually. The mental-health sector is being propelled by rising prevalence of mood disorders (U.S. prevalence up 10 % since 2020), expanding parity-mandated insurance coverage, and persistent provider shortages that favor scalable, multi-disciplinary clinic models like LifeStance’s.

For a deeper quantitative dive, the ValueRay platform offers granular financial and operational metrics on LFST.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income: -9.12m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 3.89 > 1.0
NWC/Revenue: 9.64% < 20% (prev 5.76%; Δ 3.88% < -1%)
CFO/TA 0.07 > 3% & CFO 150.9m > Net Income -9.12m
Net Debt (269.7m) to EBITDA (62.5m): 4.32 < 3
Current Ratio: 1.58 > 1.5 & < 3
Outstanding Shares: last quarter (388.9m) vs 12m ago 2.69% < -2%
Gross Margin: 31.46% > 18% (prev 0.31%; Δ 3115 % > 0.5%)
Asset Turnover: 64.25% > 50% (prev 57.22%; Δ 7.04% > 0%)
Interest Coverage Ratio: 0.36 > 6 (EBITDA TTM 62.5m / Interest Expense TTM 18.2m)

Altman Z'' -2.13

A: 0.06 (Total Current Assets 360.4m - Total Current Liabilities 228.6m) / Total Assets 2.15b
B: -0.38 (Retained Earnings -820.3m / Total Assets 2.15b)
C: 0.00 (EBIT TTM 6.47m / Avg Total Assets 2.13b)
D: -1.24 (Book Value of Equity -816.4m / Total Liabilities 656.2m)
Altman-Z'' Score: -2.13 = D

Beneish M -3.30

DSRI: 0.68 (Receivables 121.1m/158.2m, Revenue 1.37b/1.21b)
GMI: 0.99 (GM 31.46% / 31.20%)
AQI: 0.97 (AQ_t 0.69 / AQ_t-1 0.71)
SGI: 1.13 (Revenue 1.37b / 1.21b)
TATA: -0.07 (NI -9.12m - CFO 150.9m) / TA 2.15b)
Beneish M-Score: -3.30 (Cap -4..+1) = AA

What is the price of LFST shares?

As of February 07, 2026, the stock is trading at USD 6.83 with a total of 2,629,431 shares traded.
Over the past week, the price has changed by -3.39%, over one month by -6.18%, over three months by +9.28% and over the past year by -14.41%.

Is LFST a buy, sell or hold?

Lifestance Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy LFST.

StrongBuy: 5
Buy: 2
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the LFST price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	8.9	30.2%
Analysts Target Price	8.9	30.2%
ValueRay Target Price	6.9	1.6%

LFST Fundamental Data Overview February 02, 2026

P/E Forward = 51.2821
P/S = 2.011
P/B = 1.8424
Revenue TTM = 1.37b USD
EBIT TTM = 6.47m USD
EBITDA TTM = 62.5m USD
Long Term Debt = 269.4m USD (from longTermDebt, last quarter)
Short Term Debt = 60.1m USD (from shortTermDebt, last quarter)
Debt = 473.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 269.7m USD (from netDebt column, last quarter)
Enterprise Value = 3.02b USD (2.75b + Debt 473.6m - CCE 203.9m)
Interest Coverage Ratio = 0.36 (Ebit TTM 6.47m / Interest Expense TTM 18.2m)
EV/FCF = 25.29x (Enterprise Value 3.02b / FCF TTM 119.4m)
FCF Yield = 3.95% (FCF TTM 119.4m / Enterprise Value 3.02b)
FCF Margin = 8.73% (FCF TTM 119.4m / Revenue TTM 1.37b)
Net Margin = -0.67% (Net Income TTM -9.12m / Revenue TTM 1.37b)
Gross Margin = 31.46% ((Revenue TTM 1.37b - Cost of Revenue TTM 937.3m) / Revenue TTM)
Gross Margin QoQ = 32.04% (prev 27.34%)
Tobins Q-Ratio = 1.41 (Enterprise Value 3.02b / Total Assets 2.15b)
Interest Expense / Debt = 0.59% (Interest Expense 2.81m / Debt 473.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = 5.11m (EBIT 6.47m * (1 - 21.00%))
Current Ratio = 1.58 (Total Current Assets 360.4m / Total Current Liabilities 228.6m)
Debt / Equity = 0.32 (Debt 473.6m / totalStockholderEquity, last quarter 1.49b)
Debt / EBITDA = 4.32 (Net Debt 269.7m / EBITDA 62.5m)
Debt / FCF = 2.26 (Net Debt 269.7m / FCF TTM 119.4m)
Total Stockholder Equity = 1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.43% (Net Income -9.12m / Total Assets 2.15b)
RoE = -0.62% (Net Income TTM -9.12m / Total Stockholder Equity 1.47b)
RoCE = 0.37% (EBIT 6.47m / Capital Employed (Equity 1.47b + L.T.Debt 269.4m))
RoIC = 0.29% (NOPAT 5.11m / Invested Capital 1.74b)
WACC = 7.29% (E(2.75b)/V(3.22b) * Re(8.47%) + D(473.6m)/V(3.22b) * Rd(0.59%) * (1-Tc(0.21)))
Discount Rate = 8.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.33%
[DCF Debug] Terminal Value 73.57% ; FCFF base≈85.7m ; Y1≈56.2m ; Y5≈25.7m
Fair Price DCF = 0.78 (EV 574.3m - Net Debt 269.7m = Equity 304.5m / Shares 389.0m; r=7.29% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 89.58 | EPS CAGR: 90.84% | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.05 | Revenue CAGR: 18.91% | SUE: 1.36 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.05 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.25 | Chg30d=+0.024 | Revisions Net=+1 | Growth EPS=+21.1% | Growth Revenue=+14.3%

Additional Sources for LFST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle